McKesson MCK Business Segments
| TTM Q4 '26 | TTM Q3 '26 | TTM Q2 '26 | TTM Q1 '26 | TTM Q4 '25 | ||
|---|---|---|---|---|---|---|
| Total revenues by Business | ||||||
| Medical-Surgical Solutions | $11.51B+1.1% | $11.49B+1.1% | $11.45B0.0% | $11.45B+1.0% | $11.38B+0.7% | |
| North American Pharmaceutical | $336.65B+10.6% | $334.48B+14.2% | $327.35B+18.2% | $320.89B+22.3% | $304.51B+16.5% | |
| Oncology & Multispecialty | $48.42B+31.4% | $45.14B+28.8% | $41.63B+25.4% | $38.74B+22.4% | $36.86B+20.9% | |
| Prescription Technology Solutions | $5.81B+11.3% | $5.65B+11.7% | $5.52B+12.9% | $5.41B+13.5% | $5.22B+9.4% | |
| Subtotal by Business | ||||||
| Medical-Surgical Solutions | $938M+21.0% | $933M+18.6% | $937M+23.9% | $808M-10.6% | $775M-18.8% | |
| North American Pharmaceutical | $3.66B+24.2% | $3.65B+53.6% | $3.34B+50.7% | $2.84B+15.5% | $2.95B+26.0% | |
| Oncology & Multispecialty | $1.15B+49.8% | $1.07B+46.5% | $963M+37.3% | $831M+22.5% | $767M+8.5% | |
| Prescription Technology Solutions | $1.04B+19.3% | $1.01B+20.4% | $964M+16.8% | $925M+11.5% | $875M+4.8% | |
| Total other segment expense, net by Business | ||||||
| Medical-Surgical Solutions | $10.57B-0.4% | $10.56B-0.1% | $10.51B+0.3% | $10.64B+4.2% | $10.61B+2.5% | |
| North American Pharmaceutical | $332.99B+10.4% | $330.82B+13.9% | $324.01B+17.9% | $318.05B+22.4% | $301.56B+16.4% | |
| Oncology & Multispecialty | $47.27B+31.0% | $44.08B+28.4% | $40.66B+25.2% | $37.91B+22.4% | $36.1B+21.2% | |
| Prescription Technology Solutions | $4.76B+9.7% | $4.64B+9.7% | $4.56B+12.1% | $4.48B+12.4% | $4.34B+10.3% | |
| Revenue derived from services (less than) (as a percent) by Business | ||||||
| Prescription Technology Solutions | 118%0.0pp | 118%— | 118%— | 118%— | 118%— | |
| Total segment expenditures for long-lived assets by Business | ||||||
| Medical-Surgical Solutions | $94M-42.3% | $115M-31.9% | $127M-26.4% | $137M-19.5% | $163M+2.5% | |
| North American Pharmaceutical | $334M+37.4% | $304M+53.7% | $282M+60.7% | $274M+83.6% | $243M+52.8% | |
| Oncology & Multispecialty | $78M-11.4% | $88M0.0% | $98M+15.3% | $94M+4.4% | $88M-8.3% | |
| Prescription Technology Solutions | $4M-63.6% | $3M-83.1% | $5M-77.8% | $8M-70.6% | $11M-64.5% | |
| Other by Business | ||||||
| Medical-Surgical Solutions | $2M+200% | $1.5M+175% | -$1M— | -$1.5M— | -$2M— | |
| Oncology & Multispecialty | $0+100% | -$250K— | -$500K— | -$750K— | -$1M— | |
| Total segment depreciation and amortization by Business | ||||||
| Medical-Surgical Solutions | $96M+4.3% | $95M+7.3% | $92M+7.0% | $91M+7.7% | $92M+12.2% | |
| North American Pharmaceutical | $134M-13.5% | $129M-25.5% | $128M-32.5% | $139M-29.0% | $155M-21.3% | |
| Oncology & Multispecialty | $240M+62.2% | $212M+45.0% | $186M+29.6% | $152M+8.0% | $148M+8.0% | |
| Prescription Technology Solutions | $82M-4.7% | $83M-3.5% | $84M-1.2% | $86M+2.4% | $86M+2.4% | |
| Foreign currency translation adjustments, net by Business | ||||||
| Medical-Surgical Solutions | $0— | $0— | $0— | $0— | $0— | |
| Prescription Technology Solutions | $0— | $0— | $0— | $0— | $0— | |
| Total reserve balance by Business | ||||||
| Medical-Surgical Solutions | $112M-67.5% | $192M-25.0% | $297M+102% | $402M+6,600% | $345M+3,733% | |
| Prescription Technology Solutions | $4M-66.7% | $2M-87.5% | $4M-78.9% | $8M— | $12M— | |
| Other adjustments by Business | ||||||
| Medical-Surgical Solutions | $0— | $83M— | —— | —— | —— | |
| Prescription Technology Solutions | -$1M— | -$8M— | -$8M— | —— | —— | |
| Non-cash charges by Business | ||||||
| Medical-Surgical Solutions | -$8M-157% | $19M+217% | $14M— | $14M— | $14M— | |
| Prescription Technology Solutions | $17M+88.9% | $7M+250% | $7M— | $8M— | $9M— | |
| Severance and employee-related costs, net by Business | ||||||
| North American Pharmaceutical | $9M+400% | $0-100% | $0-100% | -$3M-157% | -$3M-143% | |
| Restructuring Charges by Business | ||||||
| Medical-Surgical Solutions | $43M-78.9% | $68M-60.2% | $90M-41.9% | $218M+1,717% | $204M+1,755% | |
| North American Pharmaceutical | $24M— | —— | —— | —— | —— | |
| Prescription Technology Solutions | $20M+66.7% | $7M-22.2% | $7M-36.4% | $8M-38.5% | $12M+9.1% | |
| Payments for Restructuring by Business | ||||||
| Medical-Surgical Solutions | $133M+34.3% | $178M+230% | $179M+1,179% | $145M+867% | $99M+662% | |
| Oncology & Multispecialty | $0-100% | $500K— | $1M— | $1.5M— | $2M— | |
| Exit and other-related costs by Business | ||||||
| Medical-Surgical Solutions | $37M-30.2% | $56M+100% | $73M+508% | $62M+377% | $53M+342% | |
| North American Pharmaceutical | $3M0.0% | $5M+567% | $6M+1,100% | $4M+77.8% | $3M0.0% | |
| Goodwill, transfer to held-for-sale by Business | ||||||
| Medical-Surgical Solutions | $0— | $0— | $0— | —— | —— | |
| Oncology & Multispecialty | $9M— | $6.75M— | $4.5M— | $2.25M— | $0— | |
| Prescription Technology Solutions | $0— | $0— | $0— | —— | —— | |
| Asset impairments and accelerated depreciation by Business | ||||||
| North American Pharmaceutical | $12M— | —— | —— | —— | —— | |
| Goodwill by Business | ||||||
| Medical-Surgical Solutions | $10.03B-0.3% | $10.03B+0.2% | $10.03B+0.8% | $10.03B+1.3% | $10.06B+2.5% | |
| Prescription Technology Solutions | $8.26B+2.0% | $8.23B+1.6% | $8.18B+1.3% | $8.14B+1.0% | $8.1B+0.7% | |
| Goodwill acquired by Business | ||||||
| Medical-Surgical Solutions | $0— | $0— | $0— | —— | —— | |
| Total long-lived assets by Geography | ||||||
| Foreign | $1.1B— | $1.15B— | —— | —— | —— | |
| United States | $12.35B— | $12.05B— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does McKesson break its business down?
- McKesson (MCK) reports total revenues by business across 4 parts — Medical-Surgical Solutions, North American Pharmaceutical, Oncology & Multispecialty and Prescription Technology Solutions. Each is extracted from the segment footnotes and tracked over time.
- Where does McKesson's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in McKesson's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
